5 results about "Interleukin-4 receptor" patented technology

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

This invention relates to an antisense oligonucleotide targeting the interleukin-4 receptor and its applications. The antisense oligonucleotide (ASO) molecule is 16-22 bases in length and specifically pairs with a specific region of the target gene (interleukin-4 receptor). The ASO is used to treat diseases related to IL-4Rα, including but not limited to asthma (including eosinophilic types), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, nodular prurigo, urticaria, COPD, bullous pemphigoid, pruritus, and gastritis.

The present invention relates to a biomarker for predicting therapeutic response in asthma patients and a use thereof, and specifically, to a method for predicting therapeutic response to an anti-interleukin 4 receptor antibody (anti-IL-4R antibody), an anti-interleukin 5 antibody (anti-IL-5 antibody), or an anti-interleukin 5 receptor antibody (anti-IL-5R antibody), which is being used as a therapeutic agent for asthma, by using eicosanoids, and the like.

Provided are an interleukin 4 receptor (IL-4R) binding molecule and a use thereof. A heavy chain variable region of the molecule comprises a heavy chain complementarity-determining region 1 (HCDR1), a heavy chain complementarity-determining region 2 (HCDR2), and a heavy chain complementarity-determining region 3 (HCDR3), wherein HCDR1 comprises an amino acid sequence as shown in SEQ ID NO: 1, 4, 6, 9, 12, or 15 or any variant thereof; HCDR2 comprises an amino acid sequence as shown in SEQ ID NO: 2, 7, 10, 13, or 111 or any variant thereof; and HCDR3 comprises an amino acid sequence as shown in SEQ ID NO: 3, 5, 8, 11, 14, or 112 or any variant thereof. The antibody can significantly block the binding of IL-4 to IL-4R, and exhibits IL-4R signal blocking activity significantly superior to that of the positive control antibody dupilumab.

The present invention relates to the technical field of biological detection, and provides a primer probe set for detecting human interleukin 4 receptor α (IL4RA) mRNA, a kit, and a use thereof. The primer probe set of the present invention comprises IL4RA-F, IL4RA-R and a probe I4-Probe; the nucleotide sequence of IL4RA-F is shown in SEQ ID NO: 1, the nucleotide sequence of IL4RA-R is shown in SEQ ID NO: 2, and the nucleotide sequence of probe I4-Probe is shown in SEQ ID NO: 3. The present invention provides a kit comprising the primer probe set, which can detect the expression level of IL4RA mRNA by using an RNA one-step method, and provides a detection means having high accuracy, a broad detection range and high sensitivity for the detection of IL4RA protein.